GLP-1 RAs for Treating Metabolic Dysfunction-Associated Steatosis Liver Disease: From GLP-1 Discovery to FDA...

Area of Science:

• Hepatology
• Endocrinology
• Pharmacology

Background:

• Metabolic dysfunction-associated steatosis liver disease (MASLD), previously NAFLD, is the leading cause of chronic liver disease globally.
• Current management relies on lifestyle changes and weight loss, which are challenging for patients to achieve and maintain.
• The lack of approved pharmacological treatments has limited clinical options for MASLD.

Purpose of the Study:

• To review the scientific evidence supporting the approval of GLP-1RAs for MASLD.
• To synthesize findings from in vitro, animal, and clinical studies.
• To discuss future research directions for optimizing GLP-1RA therapy in MASLD.

Main Methods:

• Review of in vitro studies using hepatocellular and multicellular models.
• Analysis of preclinical data from animal models of steatosis-induced liver injury.
• Examination of clinical trial results in patients with MASLD and its inflammatory subtype.

Main Results:

• GLP-1RAs demonstrate efficacy in reducing hepatic steatosis.
• These agents attenuate inflammatory pathways involved in liver disease progression.
• GLP-1RAs represent the first pharmacological class with multi-level efficacy for MASLD.

Conclusions:

• GLP-1RAs are a significant advancement in MASLD pharmacotherapy.
• Evidence supports their role in reducing liver fat and inflammation.
• Further research is needed to optimize their therapeutic use and address remaining questions.